Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Abbott earns approval in Japan for Xience Xpedition everolimus-eluting stent. Zimmer will distribute SpineCraft’s APEX system. More new product news.

You may also be interested in...



Perseon Cancer Ablation Therapy Expanded To Treat Liver Tumors

The newly renamed company says FDA has cleared its MicroThermX microwave ablation system to treat complicated non-resectable liver tumors.

People Briefs: BSD Medical CEO; TransEnterix COO Resigns; Delphinus Medical

Device industry veteran Clint Carnell named president and CEO of BSD Medical; TransEnterix reports resignation of chief operating officer; Delphinus Medical Technologies appoints VP, finance.

New Product Briefs: Smartphone Glucose Monitor; OTC Pain Device

The world’s smallest, FDA-cleared mobile blood glucose monitor, a chronic pain device goes OTC, and Covidien launches peripheral thrombolysis device.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel